<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00125515</url>
  </required_header>
  <id_info>
    <org_study_id>#4847/R01-15822</org_study_id>
    <secondary_id>K23DA000429</secondary_id>
    <nct_id>NCT00125515</nct_id>
  </id_info>
  <brief_title>Memantine and Naltrexone Treatment for Opioid Dependence</brief_title>
  <acronym>NAMHS-1</acronym>
  <official_title>Evaluation of NMDA Antagonist for Opiate Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to test the efficacy of memantine (a noncompetitive NMDA receptor
      antagonist) as an adjunct to the maintenance treatment with naltrexone in detoxified
      heroin-dependent individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim of this study is to test the efficacy of memantine, a noncompetitive NMDA
      receptor antagonist, in reducing early attrition and improving outcome in opioid-dependent
      individuals maintained on naltrexone.

      This double-blind, 12-week trial will include heroin-dependent patients who completed
      detoxification. Participants will be randomly assigned to one of three conditions: naltrexone
      and placebo, naltrexone and memantine (15 mg bid), or naltrexone and memantine (30 mg bid).
      Naltrexone will be taken 3 times each week at the clinic, while memantine or placebo will be
      taken at home. In addition, twice each week patients will receive a psychosocial intervention
      that will include motivational interviewing and cognitive-behavioral relapse prevention. The
      goal of the psychosocial intervention is to improve compliance with medication and maintain
      abstinence. Baseline assessments will be taken and compared to those completed at study
      visits, which will occur 3 times each week.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retention in Treatment</measure>
    <time_frame>Number of participants who complete 12 weeks of treatment</time_frame>
    <description>The number of participants who were retained and completed all 12 weeks of treatment and study participation were compared between the three study groups.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Opioid Dependence</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo plus oral naltrexone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Memantine 30 mg bid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Memantine 30 mg bid plus oral naltrexone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Memantine 15 mg bid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>memantine 15 mg bid plus oral naltrexone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine</intervention_name>
    <description>One arm receives 30 mg bid and the other arm receives receives 15mg bid</description>
    <arm_group_label>Memantine 30 mg bid</arm_group_label>
    <arm_group_label>Memantine 15 mg bid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>Patients received the equivalent of 50 mg/day. Dispensed as 100 mg on Mondays and Wednesdays and 150 mg on Fridays.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Memantine 30 mg bid</arm_group_label>
    <arm_group_label>Memantine 15 mg bid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Adult, aged 18-60.

          -  Meets DSM-IV criteria for current opiate dependence disorder of at least six months
             duration, supported by a positive urine for opiates and a positive naloxone challenge
             test if the diagnosis is unclear.

          -  Able to give informed consent.

        Exclusion:

          -  Pregnancy or breastfeeding

          -  Failure in a sexually active woman to use adequate contraceptive methods

          -  Active medical illness that might make participation hazardous, such as untreated
             hypertension, acute hepatitis with SGOT or SGPT levels &gt; 2 times normal, unstable
             diabetes, or chronic organic mental disorder (e.g., AIDS dementia)

          -  Active psychiatric disorder that might interfere with participation or make
             participation hazardous, including DSM-IV schizophrenia, bipolar disorder with mania
             or psychosis, and depressive disorder with suicide risk or 1 or more suicide attempts
             within the past year.

          -  History of allergic reaction to buprenorphine, naloxone, memantine, naltrexone,
             clonidine, or clonazepam

          -  Currently prescribed or regularly taking opiates for chronic pain or medical illness

          -  Current participation in another intensive psychotherapy or substance abuse treatment
             program or currently prescribed psychotropic medications

          -  Current participation in a methadone maintenance treatment program and/or regular use
             of illicit methadone ( &gt; 30 mg per week)

          -  History of accidental drug overdose in the last 3 years or any other significant
             history of overdose following detoxification, defined as an episode of opioid-induced
             unconsciousness or incapacitation, whether or not medical treatment was sought or
             received
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Bisaga, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://stars.columbia.edu</url>
    <description>stars website</description>
  </link>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2005</study_first_submitted>
  <study_first_submitted_qc>July 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2005</study_first_posted>
  <results_first_submitted>December 18, 2012</results_first_submitted>
  <results_first_submitted_qc>December 18, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 24, 2013</results_first_posted>
  <last_update_submitted>January 28, 2013</last_update_submitted>
  <last_update_submitted_qc>January 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heroin</keyword>
  <keyword>Opiates</keyword>
  <keyword>naltrexone</keyword>
  <keyword>memantine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Individuals who applied for treatment at the Columbia University's Substance Treatment and Research Service outpatient clinic in New York City were recruited for this study.</recruitment_details>
      <pre_assignment_details>Following consent participants were admitted to an inpatient unti at NYSPI for the purpose od detoxification and naltrexone induction. On the second day of induction they were randomized to a study arm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo plus oral naltrexone</description>
        </group>
        <group group_id="P2">
          <title>Memantine 30 mg Bid</title>
          <description>Memantine 30 mg bid plus oral naltrexone</description>
        </group>
        <group group_id="P3">
          <title>Memantine 15 mg Bid</title>
          <description>memantine 15 mg bid plus oral naltrexone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo plus oral naltrexone</description>
        </group>
        <group group_id="B2">
          <title>Memantine 30 mg Bid</title>
          <description>Memantine 30 mg bid plus oral naltrexone</description>
        </group>
        <group group_id="B3">
          <title>Memantine 15 mg Bid</title>
          <description>memantine 15 mg bid plus oral naltrexone</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="27"/>
            <count group_id="B4" value="81"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.5" spread="9.6"/>
                    <measurement group_id="B2" value="42.0" spread="10.3"/>
                    <measurement group_id="B3" value="41.5" spread="9.4"/>
                    <measurement group_id="B4" value="41.3" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Retention in Treatment</title>
        <description>The number of participants who were retained and completed all 12 weeks of treatment and study participation were compared between the three study groups.</description>
        <time_frame>Number of participants who complete 12 weeks of treatment</time_frame>
        <population>All analysis were conducted based on intent-to-treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo plus oral naltrexone</description>
          </group>
          <group group_id="O2">
            <title>Memantine 30 mg Bid</title>
            <description>Memantine 30 mg bid plus oral naltrexone</description>
          </group>
          <group group_id="O3">
            <title>Memantine 15 mg Bid</title>
            <description>memantine 15 mg bid plus oral naltrexone</description>
          </group>
        </group_list>
        <measure>
          <title>Retention in Treatment</title>
          <description>The number of participants who were retained and completed all 12 weeks of treatment and study participation were compared between the three study groups.</description>
          <population>All analysis were conducted based on intent-to-treat principle.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>all statistical analysis were two tailed and employed an alpha significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.32</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo plus oral naltrexone</description>
        </group>
        <group group_id="E2">
          <title>Memantine 30 mg Bid</title>
          <description>Memantine 30 mg bid plus oral naltrexone</description>
        </group>
        <group group_id="E3">
          <title>Memantine 15 mg Bid</title>
          <description>memantine 15 mg bid plus oral naltrexone</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>heroin overdose</sub_title>
                <description>Overdose requiring hospitalization following relapse to heroin use.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>GI distress</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="27"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>body aches</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>It is possible that concomitant naltrexone might have exacerbated protracted withdrawal, thus masking the potential ameliorative effects of memantine that have been previously observed in other trials.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Adam Bisaga</name_or_title>
      <organization>New York Psychiatric Institute</organization>
      <phone>212-543-6542</phone>
      <email>bisagaa@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

